Should Biotech Startups Raise Less Money Early?
A venture investor who spent 20 years as a general partner at Sequoia Capital went back through the data on Silicon Valley startups. He found something he did not expect: the amount a company raised in its early rounds ran against its eventual success. Mike Goguen, now founder and managing partner of Two Bear Capital, described that finding on Open Door Salon and was careful not to turn it into a rule. The honest version is a correlation with a plausible mechanism behind it. What follows is what he said and why he thinks it happens. After that comes the structural version of the same conversation from Christian Schubert of AbbVie Ventures, who sizes checks under a constraint most funds do not carry.
What did the data actually show?
Goguen described a backward-looking analysis across a large set of Silicon Valley startups, and the result surprised him.
The amount raised, especially in the early stage, was almost inversely correlated with the success.
Two words in that sentence are doing a great deal of work. Almost and correlated. He did not say large early rounds cause failure, and he explicitly declined to treat the pattern as deterministic. He also confined it to the early stage, where he and Schubert both invest, and where the dynamics differ sharply from growth rounds anchored to public-market comparables.
Why would raising more money make a company worse?
The mechanism Goguen offered is behavioral, and it concerns how a well-funded team allocates attention.
It’s sort of human nature that if you have that plenty that early in a company, your razor-sharp thinking might be a little dull in terms of what you’re investing it, what you’re putting the money behind.
Scarcity forces a team to choose which experiments matter. Abundance removes the forcing function at exactly the stage where choosing well compounds hardest. He was careful to bound this too, noting that the discipline is valuable only up to the point where it stops being detrimental to the mission. Underfunding a company short of a real milestone is its own failure, and he said so directly.
What test does an investor apply to a first check?
Goguen described a question about what the money buys.
Is there a very high probability that that will be a meaningful enough inflection point, the next round will be easy?
That reframes the decision usefully. The right amount is whatever reliably reaches the next point at which the company is worth demonstrably more, with enough margin for the biology to misbehave. A round sized above that threshold buys optionality the team may not use well. A round sized below it buys a down round. Neither number is knowable from a benchmark table, which is why the question is about the milestone.
How does a corporate fund size a check differently?
Schubert has a constraint that changes the arithmetic, and it comes from the parent company.
Generally we try to stay below 20% in truly minority ownership territory.
AbbVie Ventures invests off a corporate balance sheet, so its CFO office carries consolidation expectations. Staying under 20% keeps the investment in genuine minority territory, which caps how much the fund can put into an early round regardless of conviction. That constraint quietly protects the founder from a particular failure mode.
What happens when a fund overpays early?
Schubert described the trade directly, and it is the practical reason a founder should care about round size at all.
In theory we could put in more money, but then the valuation would be sky-high.
A valuation set too high in an early round has to be cleared by the next one. If the milestones do not arrive on schedule, and in biotech they frequently do not, the following round prices lower and the company takes a down round with all the signaling and dilution that carries. Schubert said his fund has told companies to take less money, or to accept a valuation at the lower end of current market expectations, precisely so institutional investors can come in later without that problem.
So should a biotech startup raise less money early?
The defensible answer is that a founder should raise the amount that reaches a genuine inflection point with margin, and treat any excess above that as a cost. Neither investor endorsed raising less as a strategy in itself. Both described a discipline about what the round is for. The correlation Goguen found is consistent with that discipline and does not replace it. A founder who raises artificially little to imitate a pattern has simply found a new way to run out of money before the data arrives.
Where does this leave a founder in a hard market?
In a market where capital is harder to raise, this reads as unexpectedly good news. The round a founder can actually get may be closer to the round that correlates with better outcomes than the mega-round they cannot. Goguen made the related point elsewhere in the conversation that early-stage fundamentals and early-stage valuations move much less with the cycle than later rounds do. The company still has to pick the right experiments, which is the part no round size solves.
The full conversation is on the Open Door Salon episode page, drawn from the recorded, on-the-record discussion; quotes are lightly edited for clarity, and the full episode is the record. It sits alongside the same investors on how many pitches a fund reviews before investing and on whether warm introductions still matter. If your organization wants to reach this audience, partner with Open Door Salon.